I love Thanksgiving for a number of reasons, the two biggest of which are 1) pie and 2) the explicit focus on gratitude. This year, I’ve been especially fortunate. As

So I wasn’t gone that long, but I feel like I missed a ton. Eschewing the usual format in favor of some quick hits, grouped by importance. BIG DEALS The

My goal for The Arc is to have some sort of a spin on some element of the news, rather than just a Chat-GPT-sounding summary of whatever tabs I have

Generally, I try to reserve Inflection Point for breaking news, and it’s tough to justify highlighting a Wall Street Journal editorial in this slot. Bear with me.  The WSJ editorial

Programming Note: Cost Curve will be off Thursday, Friday, and next Monday so that I can watch my social media manager/future Terrier do her thing against some of Canada’s best

The PhRMA Medicines in Development reports are almost hard to read because it’s hard to wrap your head around some of the numbers. The latest from the group looks at

Look, you’ve all seen the news, so I probably don’t need to provide the details: Lilly won FDA approval for Zepbound in obesity. It’s the same ingredient in Mounjaro and

The Wall Street Journal covered, with some depth, the trend of biosimilars launching with two prices: a low price designed to be appealing to consumers (and, I guess, media) and

Look, the evidence is clear: hospitals are taking in a ton of 340B money, and we don’t know where it goes. But the circumstantial evidence is that it doesn’t go

It’s moving week at the Cost Curve offices, so the newsletter -- while it will appear -- is going to show up at slightly more random times. Thanks for your